Control of Leukocyte Function
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/29/2018 |
| Start Date: | January 2007 |
| End Date: | December 15, 2017 |
The protocol is to draw peripheral blood from healthy volunteers for in vitro studies. The
aims of these in vitro studies are to determine the cellular and intracellular mechanisms by
which hypertonic saline and ATP release regulate neutrophil and lymphocyte functions.
aims of these in vitro studies are to determine the cellular and intracellular mechanisms by
which hypertonic saline and ATP release regulate neutrophil and lymphocyte functions.
The proper regulation of leukocyte function is critical for immune defense and to prevent
autoimmune diseases. Many aspects of immune cell regulation are unknown. A better
understanding could lead to novel therapeutic approaches to improve immune function in
patients suffering from various diseases.
The investigators have found that hypertonic conditions regulate leukocyte functions through
feedback mechanisms involving ATP release and purinergic receptors. The purpose of the
proposed protocol is to obtain access to peripheral blood from healthy volunteers to study
these complex regulatory mechanisms in more detail.
autoimmune diseases. Many aspects of immune cell regulation are unknown. A better
understanding could lead to novel therapeutic approaches to improve immune function in
patients suffering from various diseases.
The investigators have found that hypertonic conditions regulate leukocyte functions through
feedback mechanisms involving ATP release and purinergic receptors. The purpose of the
proposed protocol is to obtain access to peripheral blood from healthy volunteers to study
these complex regulatory mechanisms in more detail.
Inclusion Criteria:
- any healthy volunteer
Exclusion Criteria:
- pregnancy
- needing/using drugs
- inflammatory or infectious complications
We found this trial at
1
site
